Cargando…

Intracranial Virotherapy for a Canine Hemangioma

Intracranial hemangiomas are rare neoplastic lesions in dogs that usually appear with life-threatening symptoms. The treatment of choice is tumor resection; however, complete resection is rarely achieved. The patient’s prognosis therefore usually worsens due to tumor progression, and adjuvant treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Delgado-Bonet, Pablo, Tomeo-Martín, Beatriz Davinia, Delgado-Bonet, Blanca, Sardón-Ruiz, David, Torrado-Carvajal, Angel, Mateo, Isidro, Perisé-Barrios, Ana Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569716/
https://www.ncbi.nlm.nih.gov/pubmed/36232978
http://dx.doi.org/10.3390/ijms231911677
_version_ 1784809923768483840
author Delgado-Bonet, Pablo
Tomeo-Martín, Beatriz Davinia
Delgado-Bonet, Blanca
Sardón-Ruiz, David
Torrado-Carvajal, Angel
Mateo, Isidro
Perisé-Barrios, Ana Judith
author_facet Delgado-Bonet, Pablo
Tomeo-Martín, Beatriz Davinia
Delgado-Bonet, Blanca
Sardón-Ruiz, David
Torrado-Carvajal, Angel
Mateo, Isidro
Perisé-Barrios, Ana Judith
author_sort Delgado-Bonet, Pablo
collection PubMed
description Intracranial hemangiomas are rare neoplastic lesions in dogs that usually appear with life-threatening symptoms. The treatment of choice is tumor resection; however, complete resection is rarely achieved. The patient’s prognosis therefore usually worsens due to tumor progression, and adjuvant treatments are required to control the disease. Oncolytic viruses are an innovative approach that lyses the tumor cells and induces immune responses. Here, we report the intratumoral inoculation of ICOCAV15 (an oncolytic adenovirus) in a canine intracranial hemangioma, as adjuvant treatment for incomplete tumor resection. The canine patient showed no side effects, and the tumor volume decreased over the 12 months after the treatment, as measured by magnetic resonance imaging using volumetric criteria. When progressive disease was detected at month 18, a new dose of ICOCAV15 was administered. The patient died 31.9 months after the first inoculation of the oncolytic adenovirus. Furthermore, tumor-infiltrated immune cells increased in number after the viral administrations, suggesting tumor microenvironment activation. The increased number of infiltrated immune cells, the long survival time and the absence of side effects suggest that ICOCAV15 could be a safe and effective treatment and should be further explored as a novel therapy for canine hemangiomas.
format Online
Article
Text
id pubmed-9569716
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95697162022-10-17 Intracranial Virotherapy for a Canine Hemangioma Delgado-Bonet, Pablo Tomeo-Martín, Beatriz Davinia Delgado-Bonet, Blanca Sardón-Ruiz, David Torrado-Carvajal, Angel Mateo, Isidro Perisé-Barrios, Ana Judith Int J Mol Sci Case Report Intracranial hemangiomas are rare neoplastic lesions in dogs that usually appear with life-threatening symptoms. The treatment of choice is tumor resection; however, complete resection is rarely achieved. The patient’s prognosis therefore usually worsens due to tumor progression, and adjuvant treatments are required to control the disease. Oncolytic viruses are an innovative approach that lyses the tumor cells and induces immune responses. Here, we report the intratumoral inoculation of ICOCAV15 (an oncolytic adenovirus) in a canine intracranial hemangioma, as adjuvant treatment for incomplete tumor resection. The canine patient showed no side effects, and the tumor volume decreased over the 12 months after the treatment, as measured by magnetic resonance imaging using volumetric criteria. When progressive disease was detected at month 18, a new dose of ICOCAV15 was administered. The patient died 31.9 months after the first inoculation of the oncolytic adenovirus. Furthermore, tumor-infiltrated immune cells increased in number after the viral administrations, suggesting tumor microenvironment activation. The increased number of infiltrated immune cells, the long survival time and the absence of side effects suggest that ICOCAV15 could be a safe and effective treatment and should be further explored as a novel therapy for canine hemangiomas. MDPI 2022-10-02 /pmc/articles/PMC9569716/ /pubmed/36232978 http://dx.doi.org/10.3390/ijms231911677 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Delgado-Bonet, Pablo
Tomeo-Martín, Beatriz Davinia
Delgado-Bonet, Blanca
Sardón-Ruiz, David
Torrado-Carvajal, Angel
Mateo, Isidro
Perisé-Barrios, Ana Judith
Intracranial Virotherapy for a Canine Hemangioma
title Intracranial Virotherapy for a Canine Hemangioma
title_full Intracranial Virotherapy for a Canine Hemangioma
title_fullStr Intracranial Virotherapy for a Canine Hemangioma
title_full_unstemmed Intracranial Virotherapy for a Canine Hemangioma
title_short Intracranial Virotherapy for a Canine Hemangioma
title_sort intracranial virotherapy for a canine hemangioma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569716/
https://www.ncbi.nlm.nih.gov/pubmed/36232978
http://dx.doi.org/10.3390/ijms231911677
work_keys_str_mv AT delgadobonetpablo intracranialvirotherapyforacaninehemangioma
AT tomeomartinbeatrizdavinia intracranialvirotherapyforacaninehemangioma
AT delgadobonetblanca intracranialvirotherapyforacaninehemangioma
AT sardonruizdavid intracranialvirotherapyforacaninehemangioma
AT torradocarvajalangel intracranialvirotherapyforacaninehemangioma
AT mateoisidro intracranialvirotherapyforacaninehemangioma
AT perisebarriosanajudith intracranialvirotherapyforacaninehemangioma